Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mifepristone: a potential contraceptive

O Heikinheimo1, D F Archer

  • 1University of Helsinki, Finland.

Clinical Obstetrics and Gynecology
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormonal contraception and risk of major adverse cardiovascular events: A nationwide registry study from Finland.

Contraception·2025
Same author

Risk factors for lichen planus in women: A population-based case-control study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

First live birth before surgical verification of endometriosis-a nationwide register study of 18 324 women.

Human reproduction (Oxford, England)·2023
Same author

Ethinylestradiol in combined hormonal contraceptive has a broader effect on serum proteome compared with estradiol valerate: a randomized controlled trial.

Human reproduction (Oxford, England)·2022
Same author

Uterine bleeding with hormone therapies in menopausal women: a systematic review.

Climacteric : the journal of the International Menopause Society·2020
Same author

A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause.

Climacteric : the journal of the International Menopause Society·2020

Antiprogestins, like mifepristone, show promise for emergency contraception and treating conditions like endometriosis. Further research is needed for widespread contraceptive use.

Area of Science:

  • Reproductive medicine
  • Pharmacology

Background:

  • Standard estrogen-progestin contraceptives are unsuitable for certain patient groups, including cancer survivors and those with endometriosis or fibroids.
  • Current emergency postcoital contraception methods are underutilized, and continuous steroid use faces scrutiny.

Purpose of the Study:

  • To explore the potential of antiprogestins, specifically mifepristone, as an alternative contraceptive method.
  • To assess mifepristone's efficacy in emergency contraception and for managing gynecological conditions.

Main Methods:

  • Review of existing literature on mifepristone's contraceptive and therapeutic applications.
  • Analysis of potential benefits and risks associated with mifepristone use.

Main Results:

Keywords:
BiologyContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, PostcoitalContraceptive Mode Of ActionEndocrine EffectsEndocrine SystemEndometrial EffectsEndometriumFamily PlanningGenitaliaGenitalia, FemaleHormone AntagonistsHormonesLiterature ReviewOvulation SuppressionPhysiologyRu-486--administraction and dosageRu-486--side effectsRu-486--therapeutic useUrogenital SystemUterus

Related Experiment Videos

  • Mifepristone shows significant potential for emergency postcoital contraception.
  • It may offer therapeutic benefits for endometriosis and uterine fibroids.
  • Concerns regarding misuse exist but may be mitigated for single-dose applications.

Conclusions:

  • Antiprogestins, particularly mifepristone, are poised to become valuable additions to the contraceptive armamentarium.
  • Immediate postcoital and endometrial contraception are the most promising applications.
  • Further studies on administration, long-term effects, and safety are required for broader integration.